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Abstract
Background: Several serological assays have been developed to detect antibodies elicited against infections with
oncogenic human papillomavirus (HPV) type 16. The association between antibody levels measured by various assays and
subsequent HPV infection risk may differ. We compared HPV16-specific antibody levels previously measured by a virus-like
particle (VLP)-based direct enzyme-linked immunoassay (ELISA) with levels measured by additional assays and evaluated the
protection against HPV16 infection conferred at different levels of the assays.
Methodology/Principal Findings: Replicate enrollment serum aliquots from 388 unvaccinated women in the control arm of
the Costa Rica HPV vaccine trial were measured for HPV16 seropositivity using three serological assays: a VLP-based direct
ELISA; a VLP-based competitive Luminex immunoassay (cLIA); and a secreted alkaline phosphatase protein neutralization
assay (SEAP-NA). We assessed the association of assay seropositivity and risk of subsequent HPV16 infection over four years
of follow-up by calculating sampling-adjusted odds ratios (OR) and HPV16 seropositivity based on standard cutoff from the
cLIA was significantly associated with protection from subsequent HPV16 infection (OR=0.48, CI=0.27–0.86, compared
with seronegatives). Compared with seronegatives, the highest seropositive tertile antibody levels from the direct ELISA
(OR=0.53, CI=0.28–0.90) as well as the SEAP-NA (OR=0.20, CI=0.06, 0.64) were also significantly associated with
protection from HPV16 infection.
Conclusions/Significance: Enrollment HPV16 seropositivity by any of the three serological assays evaluated was associated
with protection from subsequent infection, although cutoffs for immune protection were different. We defined the assays
and seropositivity levels after natural infection that better measure and translate to protective immunity.
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Introduction
Infection with carcinogenic human papillomaviruses (HPV),
most notably types 16 and 18, is necessary for the development of
cervical cancer [1], the third most common cancer in women
worldwide [2]. While infection with HPV is quite common, with
the lifetime incidence estimated to be 80% [3], most infections
become undetectable within 1–2 years [4]. Only a small fraction of
PLOS ONE | www.plosone.org 1 January 2013 | Volume 8 | Issue 1 | e53067infections with high-risk HPV fail to clear, resulting in overt HPV
persistence [5]. Persistent HPV infection is strongly associated with
the development of cervical intraepithelial neoplasia grade 3
(CIN3), which progresses to invasive cervical cancer in a minority
of cases [6]. Immune responses generated upon HPV infection are
likely to be a critical mechanism for preventing, controlling, and
eliminating HPV infection [7].
Characterization of the immune responses to HPV virions can
help explain how prior infection or immunization protects against
future infection and associated disease. Correlates of protection are
currently still unclear. Neutralizing antibodies are expected to be
the primary immune mechanism for protection against HPV
infection [8]. Because of the role of antibodies in preventing HPV
infections, serological assays are important for measuring the
antibodies or other immune factors directed against HPV, and
these assays may identify the individuals who had mounted an
immune response to previous exposure to HPV and may be
protected against subsequent HPV infection [9].
Serological assays for HPV16 based on different biochemistry
include the competitive Luminex immunoassay (cLIA), designed to
measure antibodies against a specific neutralizing epitope [10]; the
secreted alkaline phosphatase neutralization assay, designed to
measure overall neutralizing potential, (SEAP-NA) [11]; and the
virus-like particle (VLP)-based enzyme-linked immunosorbent
assay (ELISA), designed to measure a broad spectrum of
neutralizing and non-neutralizing antibodies directed against the
L1 capsid protein [12]. Each assay provides only a partial
characterization of immune status, and comparison of seroprev-
alence across assays is complicated because the assays differ
quantitatively, i.e., by throughput and detection range, and
qualitatively, i.e., whether they detect antibodies against multiple
epitopes, which may be indicative of previous exposure, or
neutralizing antibodies that may confer immune protection.
Immune responses to HPV measured by currently available
assays may or may not predict individual protection [13], but
limited work has been done to determine if any measured immune
response can define immediate or future protection against HPV
infection or associated disease [9,14,15].
Safaeian et al. showed that women who have the highest
seropositive tertile of HPV16 and HPV18 antibody levels based on
a VLP-based direct ELISA assay are significantly protected from
subsequent infection with HPV16 and HPV18, respectively [14],
after controlling for risk factors associated with newly detected
HPV infection. Due to the potential for serological assays to
differentially measure HPV antibody levels in association with
protection from subsequent HPV infection, we compared the
previous HPV16 results obtained using a VLP-based direct ELISA
with results obtained using a VLP-based cLIA and a SEAP-NA.
Here, we aimed to identify the assays and seropositivity levels after
natural infection that better measure and translate to protective
immunity.
Materials and Methods
Study Population
We selected serum samples obtained at enrollment visit prior to
vaccination from women in the control arm of the Costa Rica
HPV16/18 Vaccine Trial (CVT), a publicly funded, randomized
trial of the efficacy of the HPV16/18 vaccine manufactured by
GlaxoSmithKline (GSK) for the prevention of HPV16/18
infection and related precancerous lesions among women.
Informed consent was received from subjects in the trial (registered
as Clinical Trial number NCT00128661), and the details of the
trial and characteristics of the trial participants have been
described elsewhere [16,17]. All study protocols were reviewed
and approved by the National Cancer Institute (NCI) and Costa
Rican Institutional Review Boards.
Biospecimens
Prior to randomization and vaccination, pelvic examinations
were conducted on all sexually experienced women, and cervical
cells were collected and placed in liquid medium (PreservCyt;
Cytyc Corporation, now Hologic, Marlborough, MA) for liquid-
based cytology (Thin-Prep; Cytyc Corporation, now Hologic) and
for cervical HPV detection. Blood was collected on all participants,
and serum samples were used for HPV serological testing by direct
ELISA as part of the trial. After vaccination, women were
followed-up annually. At each follow-up visit, cervical samples
were collected from sexually experienced women for HPV DNA
testing. The SPF10-HPV LiPA25 version 1 system (Labo
Biomedical Product, Rijswijk, The Netherlands) was used for all
HPV DNA testing, as previously described [14].
Stratified Sampling Strategy
The economical sampling strategy (Figure 1) selected 388
women from 2,814 HPV16 DNA-negative women. Sampling
strata were defined based on HPV16 serology as measured by
ELISA and incident HPV16 infection. Among 2,814 HPV16
DNA-negative women at enrollment in the control arm who had
follow-up HPV test results, 699 women were categorized as
HPV16 seropositive and 2,115 as seronegative by the VLP-based
direct ELISA at enrollment. Among the HPV16 seropositive
women, we included all 60 individuals who developed an incident
HPV16 infection and 60 women who were HPV16 seronegative at
enrollment and developed an incident HPV16 infection. We
included a subset of individuals who did not develop an incident
HPV16 infection from among the women who were HPV16
seropositive (n=243) and among those who were HPV16
seronegative (n=25) at enrollment. This targeted sampling
captured a wide range of ELISA titers, enabling us to compare
Figure 1. Consort diagram of the study population and
targeted sampling strategy for HPV16 serological assays
study. Out of the 639 women, who were HPV16 seropositive by ELISA
at enrollment and did not develop HPV16 infection over follow-up in
the population, 35 did not have enough sample volume for testing and
were excluded when drawing samples.
doi:10.1371/journal.pone.0053067.g001
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and to explore which assay best predicts protection from
subsequent incident HPV16 infection during four years of
follow-up. Identical enrollment prevaccination serum samples
from these 388 participants were tested by all three assays.
Serology Assays
All women included in this study had previous HPV16
serological measurements based on direct ELISA assays [14], a
standard measure of immunogenicity through polyclonal antibod-
ies, performed at GSK Biological in Rixensart, Belgium, as
described previously [19,20]. The standard cutoff for seropositivity
by the HPV16 VLP-based direct ELISA serology results was 8
EU/mL. The cLIA assay was performed as previously described at
PPD Vaccines, Biologics and Biomarkers (Wayne, PA), and the
standard seropositivity cutoff used for HPV16 was 20 mMU/mL
[21]. The SEAP-NA was performed as previously described at the
NCI-SAIC HPV Immunology Laboratory (Frederick, MD) [11],
and the standard seropositivity cutoff used for the HPV16 SEAP-
NA was 25.1.
Statistical Analysis
The results from each assay were dichotomized as seropositive
or seronegative based on laboratory-based standard cutoffs as
defined above. In addition, the seropositive samples were further
categorized as ‘‘low,’’ ‘‘medium,’’ and ‘‘high’’ based on tertiles.
Because our sampling scheme was based on the prior knowledge of
the ELISA results and new infection status, to avoid potentially
biased estimates, we derived all of our population-based estimates
by using inverse-probability weights to account for the stratified
sampling scheme. The sampling fraction for a stratum is the ratio
of numbers of stratum members in the stratified sample and in the
cohort. The reciprocal of the sampling fraction for a stratum
served as the weight for every individual in the stratum. Mann-
Whitney p-values were calculated for the comparison of sampling-
adjusted medians. To study the association between assay
seropositivity and subsequent risk of HPV infection, we derived
sampling-adjusted odds ratios (ORs) and 95% CIs from weighted
logistic regression. All statistical analyses were run using SAS (v
9.2) and R (v 2.11.1).
Results
Table 1 briefly summarizes the HPV16 serology results for the
388 subjects by incident HPV16 DNA infection status. The
subjects’ minimum assay values did not differ by incident HPV16
infection status. However, the maximum assay values as well as the
sampling-adjusted median values for subjects who did not develop
a new incident infection were at least as high (SEAP-NA) or higher
(ELISA and cLIA) than the maximum assay values for subjects
who did develop a new incident infection. Those who did not
develop a new incident infection had similar or higher sampling-
adjusted median assay values compared with those subjects who
did develop a new incident infection (Mann-Whitney p-values:
ELISA, 0.15; cLIA, 0.29; SEAP-NA, ,0.05). Graphical presen-
tation of the results comparing each assay by new infection status is
shown in Figure 2.
We then examined the association between enrollment HPV16
serology based on laboratory-based standard seropositivity cutoffs
and risk of incident HPV16 infection during four years of follow-
up (Table 2). Using these sampling-adjusted population estimates,
we found that 9% of the individuals who were categorized as
seropositive using laboratory-based standard cutoffs by the direct
ELISA, 5% by the cLIA, and 7% by the SEAP-NA developed an
incident infection; by contrast, 11% of individuals who were
categorized as seronegative by each assay developed an incident
infection. Enrollment HPV16 seropositivity by cLIA was signifi-
cantly associated with protection from incident HPV16 infection
(OR=0.48, 95% CI=0.27–0.86, compared with seronegatives).
However, as we found in our previous report [14], seropositivity
using the standard cutoff for the direct ELISA was not associated
with risk of incident HPV16 infection (OR=0.77, 95% CI=0.57–
1.03, compared with seronegatives). Seropositivity using the
standard cutoff for the SEAP-NA was also not associated with
risk of incident HPV16 infection (OR=0.66, 95% CI=0.31–1.41,
compared with seronegatives). In an analysis to consider the
potential for cross-protection, we found that seropositivity using
standard cutoffs for each of the three assays was not associated
with risk of incident HPV31 infection (data not shown). We also
examined these associations stratified by enrollment age and
enrollment lifetime number of sexual partners and did not observe
any differences by these strata (data not shown).
We further analyzed the enrollment HPV16 serological assay
results that were considered seropositive in tertiles and their
association with risk of incident HPV16 infection during four years
of follow-up (Table 3). In our previous report [14], we found that
compared with seronegative subjects, those who had the highest
seropositive tertile by ELISA were significantly protected from
incident infection. Here, we found that those subjects who had the
highest seropositive tertile by SEAP-NA were also significantly
protected from incident HPV16 infection. While seropositivity by
the standard cutoff for the cLIA was associated with protection
Table 1. HPV16 serology results by incident HPV16 DNA infection status for the 388 subjects selected for assay measurement.
All subjects (N=388) No new infection (N=268) New infection (N=120)
Assay Min Max
Geometric
mean
a Median
a Min Max
Geometric
mean
a Median
a Min Max
Geometric
mean
a Median
a
ELISA ,8 3202 6.79 ,8 ,8 3202 6.90 ,8 ,8 345 5.97 ,8
cLIA ,11 3370 6.91 ,11 ,11 3370 7.00 ,11 ,11 351 6.21 ,11
SEAP-NA 5 2560 11.97 12.31 5 2560 12.22 13.12 5 2560 10.05 9.03
ELISA: VLP-based direct enzyme-linked immunosorbent assay; cLIA: Competitive Luminex immunoassay; SEAP-NA: Secreted alkaline phosphatase protein neutralization
assay.
Values less than the level of quantification are shown as ‘‘,level of quantification’’.
aSampling-adjusted population estimates for the original cohort estimated using Inverse-probability weights (see methods). For calculation of sampling-adjusted values,
the assay values under the level of quantification were assumed to be midway in the range. For example, ELISA values ,8 were assumed to be 4, and cLIA values ,11
were assumed to be 5.5.
doi:10.1371/journal.pone.0053067.t001
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into tertiles did not improve the risk prediction for the cLIA assay.
Lastly, we examined the association between enrollment
HPV16 seropositivity by multiple assays and the risk of incident
HPV16 infection (Table S1A). Compared with the subjects who
were categorized as seronegative by all three assays, those subjects
who were seropositive by all three assays (using standard cutoffs)
had a significantly lower risk of developing an incident infection.
In our previous work [18], we determined that an alternate
seropositivity cutoff of 60 EU/mL for the direct ELISA leads to
better concordance between the ELISA and cLIA (at standard
cutoff). Those who were seropositive using this alternate seropos-
itivity cutoff for the ELISA had a lower risk of developing an
incident infection (OR=0.57, 95% CI=0.33–0.99). Moreover,
we also examined the strata of enrollment serology using this
alternate seropositivity cutoff for the ELISA (Table S1B) and
found similar results as before, such that subjects who were
seropositive by all three assays had a significantly lower risk of
developing an incident infection (OR=0.42, 95% CI=0.20–
0.89).
Discussion
Here, we evaluate the association between HPV16-specific
immune responses generated following natural infection by three
different serological assays and risk of subsequent HPV16
infection. We observed a significant association between enroll-
ment HPV16 seropositivity and protection from subsequent
incident HPV16 infection over four years of follow-up; however,
the extent of protection was dependent on data categorization for
individual serological assays. Women whose levels were above the
standard cutoff for the cLIA had half the risk of acquiring an
incident infection of seronegative women. The risk of subsequent
infection in women with enrollment ELISA or SEAP-NA results in
the highest seropositive tertile was significantly lower than that of
seronegative women. Also, women who were seropositive by all
three assays were less likely to acquire a subsequent incident
infection than women who were seronegative by all assays.
The currently available assays we used in this study are
heterogeneous. Our point estimates of protection for cLIA and
SEAP-NA assays were both stronger than that for the ELISA
assay. As a polyclonal antibody assay, the VLP-based direct
ELISA measures total serum anti-VLP IgG antibodies to all
epitopes presented by VLPs, and therefore, the ELISA was
designed to measure total antibodies and may be best for
measuring previous exposure to HPV, as explored in another
study of this population [22]. The ELISA does not differentiate
between type-specific conformational antibodies and type-com-
mon antibodies, which tend to be specific for epitopes presented by
denatured L1 capsid protein and are usually not neutralizing [23].
By contrast, the cLIA was designed to measure epitope-specific
antibodies; as a monoclonal antibody assay, the cLIA was
developed to specifically detect antibodies that target one
immunodominant epitope of HPV16 L1 (the V5 epitope). In
our study, the significant association between cLIA seropositivity
based on standard cutoffs and protection is an indication that the
cLIA is an assay that captures a more specific measure of
protective immunity compared with the ELISA and SEAP-NA.
These results suggest that the cLIA, using laboratory-determined,
standard seropositivity cutoffs, measures a subset of the overall
polyclonal responses measured by the ELISA. Such findings are
similar to those of a previous study that compared the ELISA and
cLIA and found the assays to be well correlated [15]; however, this
paper is the first to show correlation between the ELISA and cLIA
among non-immunized individuals.
The cLIA may not measure neutralizing antibodies as
comprehensively as the SEAP-NA because the cLIA is a limited
assay that measures a single, albeit immunodominant, neutralizing
Figure 2. Graphical presentation of the results comparing each
assay by new infection status. The results are plotted on the log
scale for each assay; the dashed lines represent the standard cutoffs for
seropositivity for the assays. (A, B, C) Blue points represent enrollment
serology results for those subjects who did not have an incident HPV16
infection, and red squares represent enrollment serology results for
subjects for whom we detected an incident HPV16 infection. New
infection was detected over four years of follow-up.
doi:10.1371/journal.pone.0053067.g002
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for the SEAP-NA was not significantly associated with protection
from incident infection, which is surprising considering that it is a
biological assay that measures neutralizing potential regardless of
immune component or mechanism and is considered the gold
standard for measuring protection through the in vivo neutraliza-
tion potential of serum. However, as a complex biological assay,
the SEAP-NA suffers from the limitation of being less reproducible
(i.e., higher % CVs) than the ELISA and Luminex-based assays.
A challenge in finding an appropriate HPV serological assay to
determine a threshold or correlate of protective immunity is that
some naturally infected individuals who do not become seropositive
using any currently available assay could still be protected against
disease following later re-infection, possibly due to cellular immune
responses [10]. Moreover, repeated exposure to HPV may lead to
stronger responses, but results from a serologic assay do not provide
a history of cumulative exposure. In our study, subjects may have
been previously exposed to HPV16 but developed protective
immune responses that were not measured by any of the serological
assays; such misclassification would have biased our results to the
null. In addition, we cannot determine whether women who were
HPV16 DNA-negative were actually exposed, although the
numbers of recent sexual partners were the same in the infected
and non-infected groups [14]. Nonetheless, we can only measure
the ‘‘failures’’ (those for whom we detected a new infection) and
derive indirect measures of protection. Another limitation is that we
do not know if the new infections over follow-up were the result of
actual new infections or reactivated infections.
Table 2. Comparison of HPV16 serology assays at enrollment and protection against incident HPV16 DNA infections during four
years of follow-up.
Enrollment
Serology
a Incident HPV16 infection
Assay New infection, N (%
b) No new infection, N (%
b) OR (95% CI)
ELISA Negative 60 (11) 25 (89) 0.77 (0.57–1.03)
c
Positive 60 (9) 243 (91)
cLIA Negative 109 (11) 183 (89) 0.48 (0.27–0.86)
b
Positive 11 (5) 85 (95)
SEAP-NA Negative 100 (11) 151 (89) 0.66 (0.31–1.41)
b
Positive 20 (7) 117 (93)
ELISA: VLP-based direct enzyme-linked immunosorbent assay; cLIA: Competitive Luminex immunoassay; SEAP-NA: Secreted alkaline phosphatase protein neutralization
assay.
aEnrollment serology based on laboratory-based standard seropositivity cutoffs: ELISA, 8 EU/mL; cLIA, 20 mMU/mL; SEAP-NA, 25.1.
bSampling-adjusted population estimates (see methods).
cBased on data from [14].
doi:10.1371/journal.pone.0053067.t002
Table 3. Odds ratios and 95% confidence intervals for seropositive tertile categorizations of HPV16 assay results at baseline and
risk of incident HPV16 DNA infection.
Enrollment Serology
a Incident HPV16 infection
Assay New infection, N (%
b) No new infection, N (%
b) OR (95% CI)
ELISA Negative 60 (11) 25 (89) ref
Low 20 (9) 73 (91) 0.81 (0.50–1.25)
c
Medium 28 (12) 86 (88) 0.95 (0.63–1.38)
c
High 12 (5) 84 (95) 0.53 (0.28–0.90)
c
cLIA Negative 109 (11) 183 (89) ref
Low 4 (6) 25 (94) 0.51 (0.18–1.43)
b
Medium 4 (6) 28 (94) 0.54 (0.19–1.50)
b
High 3 (5) 32 (95) 0.40 (0.12–1.26)
b
SEAP-NA Negative 100 (11) 151 (89) ref
Low 8 (13) 14 (87) 1.22 (0.24–6.31)
b
Medium 9 (7) 46 (93) 0.62 (0.31–1.23)
b
High 3 (2) 57 (98) 0.20 (0.06–0.64)
b
ELISA: VLP-based direct enzyme-linked immunosorbent assay; cLIA: Competitive Luminex immunoassay; SEAP-NA: Secreted alkaline phosphatase protein neutralization
assay.
aCategorization cutoffs for the ELISA: Low 8–16, Medium .16–59, High .59; CLIA: Low 20–52, Medium .52–120, High .120; SEAP-NA assay: Low 25–32.63, Medium
.32.63–93.07, High .93.07.
bSampling-adjusted population estimates (see methods).
cPreviously reported in [14].
doi:10.1371/journal.pone.0053067.t003
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findings. Protective immunity may be associated not only with
antibody levels but also with antibody affinity and avidity, which
are not measured by the assays used in this study. The correlation
between cell-mediated immunity and antibody levels may explain
some of the observed associations between antibody assays and
protective immunity to subsequent infection; at the same time, the
weakness of the correlation may explain the low ability of antibody
levels to identify who is protected from subsequent infection.
We used data and serum collected from the control arm of a
community-based vaccine trial that included women who were
selected from a population census. Rather than measuring the
serum samples from all the eligible HPV16-DNA-negative women
in the control arm by all three serological assays (n ,8400 assays),
we designed this study using knowledge of prior results that
indicated that participants with elevated HPV16 antibody levels
(by ELISA) following natural infection had a significant 50%
reduced risk of subsequent new HPV16 infection compared with
seronegatives. Therefore, we selected women based on their
enrollment ELISA seropositivity and their newly detected HPV16
infections over the four-year follow-up period. While the limitation
was that all samples were selected based on seropositivity by the
ELISA, this sampling strategy was efficient, cost-effective, and
allowed for inferences to be applied to the original control arm. To
account for the sampling strategy and avoid biased estimates, we
applied an adjustment to all estimates that were weighted to
represent the entire cohort. Antibody levels do not fully explain
subsequent protection or susceptibility for HPV infection, so there
is a continued need for valid and reliable assays to better
determine correlates of protection. Future research efforts should
be directed toward correlating measures of virus type-specific
immunity with protection against re-infection with these types and
toward determining the duration of potential cross-protection
from natural immunity.
Supporting Information
Table S1 Risk of HPV16 DNA infection in strata of
enrollment HPV16 ELISA, cLIA, and SEAP-NA serology
(DOC)
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